Hyperuricosuric calcium nephrolithiasis

Endocrinology and Metabolism Clinics of North America

Volumn 31, Issue 4, 2002, Pages 915-925

  Sorensen, Carsten M ^a   Chandhoke, Paramjit S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CALCIUM; CALCIUM OXALATE; URIC ACID; ANTIGOUT AGENT; CITRIC ACID;

CALCIUM STONE; CLINICAL EXAMINATION; CLINICAL FEATURE; CRYSTALLIZATION; HUMAN; HYPERURICOSURIA; METABOLIC DISORDER; NEPHROLITHIASIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RENOGRAPHY; REVIEW; TREATMENT INDICATION; FEMALE; GOUT; MALE; METABOLISM; PATHOLOGY; STONE FORMATION; URINE;

ALLOPURINOL; CALCIUM OXALATE; CITRATES; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; KIDNEY CALCULI; LITHIASIS; MALE; URIC ACID;

EID: 0036894432     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00038-5     Document Type: Review

References (50)

1. Yü TF, Gutman AB. Uric acid nephrolithiasis in gout. Predisposing factors. Ann Int Med. 1967;67:1333-48.
2. Ettinger B. Hyperuricosuric calcium stone disease and mixed stones. In: Coe FL, Favus MJ, Pak CYC, et al, editors. Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven; 1996. p. 851-58.
3. Menon M, Parulkar BG, Drach GW. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC, Retik AB, Vaughn ED, Wein AJ, editors. Campbell's Urology. 7th Edition. Philadelphia: WB Saunders; 1998. p. 2661-733.
4. Herring LC. Observations on the analysis of ten thousand urinary calculi. J Urol 1962;88:545-62.
5. Alvarez Arroyo MV, Traba ML, Rapado A. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones. Urol Int 1992;48:342-6.
6. Gutman A, Yü TF. Uric acid nephrolithiasis. Am J Med 1968;45:756-79.
7. Ettinger B. Does hyperuricosuria play a role in calcium oxalate lithiasis? J Urol 1989;141:738-41.
8. Lalli AF. Roetgen aspects of renal calculous disease. Urol Clin North Am 1974;1:213-27.
9. Roth R, Finlayson B. Observations on the radiopacity of stone substances with special reference to cystine. Invest Urol 1973;11:186-9.
10. Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974;291:1344-50.
11. Fellström B, Backman U, Danielson BG, Johansson G, Ljunghall S, Wikström B. Urinary excretion of urate in renal calcium stone disease and in renal tubular acidification disturbances. J Urol 1982;127:589-92.
12. Millman S, Strauss AL, Parks JH, Coe FL. Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. Kidney Int 1982;22:366-70.
13. Ettinger B, Citron JT, Tang A, Livermore B. Prophylaxis of calcium oxalate stones: Clinical trials of allopurinol, magnesium hydroxide and chlorthalidone. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, editors. Urolithiasis and Related Clinical Research. New York: Plenum Press; 1985. p. 549-52.
14. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-9.
15. Sarig S. The hyperuricosuric calcium oxalate stone former. Miner Electrolyte Metab 1987;13:251-6.
16. Hodgkinson A. Uric acid disorders in patients with calcium stones. Br J Urol 1976;48:1-5.
17. Pylpchuk G, Ehrig U, Wilson DR. Idiopathic calcium nephrolithiasis. 1. Differences in urine crystalloids, urine saturation with brushite and urine inhibitors of calcification between persons with and persons without recurrent kidney stone formation. Call Med Assoc J 1979;120:658-65.
18. Schwille P, Samberger N, Wach B. Fasting uric acid and phosphate in urine and plasma of renal calcium-stone formers. Nephron 1976;16:116-25.
19. Preminger GM. Renal calculi: Pathogenesis, diagnosis, and medical therapy. Semin Nephrol 1992;12:200-16.
20. Coe FL. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int 1978;13:418-26.
21. Coe FL, Parks JH. Hyperuricosuria and calcium nephrolithiasis. Urol Clin NA 1981;8:227-44.
22. Modlin M. The aetiology of renal stones: A new concept arising from studies on a stone-free population. Ann R Coll Surg Engl 1967;40:155-78.
23. Grover PK, Ryall RL, Marshall VR. Dissolved urate promotes calcium oxalate crystallization: Epitaxy is not the cause. Clin Sci 1993;85:303-7.
24. Lonsdale K. Epitaxy as a growth factor in urinary calculi and gallstones. Nature 1968;217:56-8.
25. Preminger GM. Medical Management of Urinary Calculus Disease Part II: Classification of Metabolic Disorders and Selective Medical Management. American Urological Association update series; 1995 [vol 14, lesson 6].
26. Shetty SD, Rivers K, Menon M. A Practical Approach to the Evaluation and Treatment of Nephrolithiasis. American Urological Association update series; 2000 [vol. 19, lesson 30].
27. Coe FL, Lawton RL, Goldstein RB, Tembe V. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med 1975;149:926-9.
28. Pak CYC, Arnold LH. Heterogenous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med 1975;149:930-2.
29. Grover KG, Ryall RL, Marshall VR. Effect of urate on calcium oxalate crystallization in human urine: Evidence for a promontory role of hyperuricosuria in urolithiasis. Clin Sci 1990;79:9-15.
30. Hallson PC, Rose GA, Sulaiman S. Urate does not influence the formation of calcium oxalate crystals in whole human urine at pH 5.3. Clin Sci 1982;62:421-5.
31. Sarig S, Hirsch D, Garti N, Goldwasser B. An extension of the concept of epitaxial growth. J Crystal Growth 1984;69:91-5.
32. Grover PK, Ryall RL, Marshall VR. Calcium oxalate crystallization in urine: Role of urate and glycosaminoglycans. Kid Int 1992;41:149-54.
33. Robertson WG, Knowles F, Peacock M. Urinary mucopolysccharide inhibitors of calcium oxalate crystallization. In: Fleisch H, Robertson WG, Smith LH, Vahlensieck W, editors. Urolithiasis Research. New York, London: Plenum Press; 1976. p. 331-4.
34. Hesse A, Wurzel H, Krampitz G, Vahlensieck W. Experimental determination of the kinetics of calcium-binding with chondroitin sulphate and the effects of uric acid on this process. Urol Res 1987;15:93-7.
35. Ryall RL, Harnett RM, Marshall VR. The effect of monosodium urate on the capacity of urine, chondroitin sulphate and heparin to inhibit calcium oxalate crystal growth and aggregation. J Urol 1986;135:174-7.
36. Goldwasser B, Sarig S, Azoury R, Wax Y, Many M. Hyperuricosuria and calcium oxalate stone formation. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, editors. Urolithiasis and Related Clinical Research. New York: Plenum; 1985. p. 859-62.
37. Ryall RL, Hibberd CM, Marshall VR. The effect of crystalline monosodium urate on the crystallization of calcium oxalate in whole human urine. Urol Res 1986;14:63-5.
38. Fellstrom B, Backman U, Danielson BG, Holmgren K, Ljunghall S, Wikstrom B. Inhibitory activity of human urine on calcium oxalate crystal growth: Effects of sodium urate and uric acid. Clin Sci 1982;62:509-14.
39. Zerwekh JE, Holt K, Pak CYC. Natural urinary macromolecular inhibitors: Attenuation of inhibitory activity by urate salts. Kidney Int 1985;23:838-41.
40. Pak CYC, Barilla DE, Holt K, Brinkley L, Tolentino R, Zerwekh J. Effect of oral purine load and allopurinol on the crystallization of calcium salts in the urines of patients with hyperuricosuric calcium urolithiasis. Am J Med 1978;65:593-9.
41. Coe FL. Hyperuricosuric calcium oxalate nephrolithiasis. In: Coe FL, editor. Nephrolithiasis. Contemporary Issues in Nephrology, vol. 5. New York: Churchill Livingstone; 1980. p. 116-35.
42. Prien EL, Prien Jr EL. Composition and structure of urinary stone. Am J Med 1968;45:654-72.
43. Pak CYC, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Inter Med 1986;146:863-7.
44. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculus recurrence but magnesium hydroxide does not. J Urol 1988;139:679-84.
45. Yendt ER, Cohanim M. Prevention of calcium stones with thiazides. Kid Int 1978;13:397-409.
46. Young Jr JL, Boswell RB, Nies AS. Severe allopurinol hypersensitivity: Association with thiazides and prior renal compromise. Arch Intern Med 1974;134:553-8.
47. Pak CYC. Medical management of nephrolithiasis. J Urol 1982;128:1157-64.
48. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria or no metabolic disorder. Ann Intern Med 1977;87:404-10.
49. Finlayson B, Reid F. The effect of allopurinol on calcium oxalate (whewellite) precipitation. Inv Urol 1978;15:489-92.
50. Finlayson B, Burns J, Smith A, Bois LD. Effect of oxipurinol and allopurinol riboside on whewellite crystallization: In vitro and in vivo observations. Inv Urol 1979;17:227-9.